Clinical Trials for Cancer Type: Liver

12 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
ECOG-EAY131 (CIRB) Molecular Analysis for Therapy Choice (MATCH) Open
SWOG-S1609 (CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Open
UCI-01-61 A Humanitarian Device Exemption Use Protocol of TheraSphere® HUD For Treatment of Unresectable Primary or Secondary Liver Cancer Open
UCI-03-03 Immunologic Factors Affecting Outcomes in Patients with Liver Cancer Open
UCI-07-40 Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Appendix T) Open
UCI-14-25 Plasma Exosome Concentration in Cancer Patients Undergoing Treatment Open
UCI-15-80 A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF /Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy Open
UCI-15-81 Phase 1 Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Hepatocellular Carcinoma Open
UCI-16-40 An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma Open
UCI-16-94 Phase IIA Single-Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti- PD-1 Monoclonal Antibody Open
UCI-16-96 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Open
UCI-17-92 TATE versus TACE, an open-label randomized study comparing TransArterial Tirapazamine Embolization versus TransArterial ChemoEmbolization in Intermediate Stage Hepatocellular Carcinoma Open